Improving the Therapeutic Ratio in Head and Neck Cancer, Volume 6

1. Overview of head and neck cancer management
2. The role of immunotherapy and molecularly targeted therapies in head and neck cancer
3. Targeting the PI3K/mTOR pathway
4. Autophagy inhibition to sensitize HNC to radiation and chemotherapy
5. Overcoming head and neck cancer stem cells
6. TAM Family proteins and therapy resistance
7. Eph/Ephrin family proteins and theapy resistance
8. Metabolic reprogramming to modulate therapeutic sensitivity
9. FGFR and cMET
10. Targeting GPCRs in HNC
11. Improving the response to immunotherapy
12. Chk1/2 inhibition in radiation and cetuximab resistance

Improving the Therapeutic Ratio in Head and Neck Cancer provides a complete review of current approaches to modulating therapeutic sensitivity in head and neck cancer. It presents a broad background of current approaches and by highlighting the potential for clinical translational, introduces a roadmap for how to move promising preclinical findings into the clinic.

The book discusses topics such as immunotherapy and molecularly targeted therapies in head and neck cancer, PI3k/mTOR pathway, autophagy inhibition to sensitize HNC to radiation and chemotherapy, TAM and Eph/Ephrin family proteins and metabolic reprogramming to modulate therapeutic sensitivity. Additionally, it details approaches to improve the response to immunotherapy, and Chk1/2 inhibition in radiation and cetuximab resistance.

This book is a valuable source to head and neck cancer researchers and advanced students, and to those studying specific approaches in other model systems and disease sites.

• Provides key scientific background for clinicians when developing novel clinical trials and important examples for basic scientists of the types of work required to move a concept from the lab to the clinic
• Presents consistent pathway diagrams in each chapter, thus making it easier to understand complicated pathways
• Includes chapter summaries of the critical next steps needed to move studies from their current state into practice changing clinical data

Cancer researchers; oncologists; graduate students